Journal
BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY
Volume 79, Issue 12, Pages 1965-1971Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/09168451.2015.1060844
Keywords
(S)-selective arylmalonate decarboxylase; activity improvement; saturation mutagenesis; (S)-profen
Categories
Funding
- Japan Society for the Promotion of Science [21350096]
- Grants-in-Aid for Scientific Research [21350096] Funding Source: KAKEN
Ask authors/readers for more resources
A bacterial arylmalonate decarboxylase (AMDase) catalyzes asymmetric decarboxylation of unnatural arylmalonates to produce optically pure (R)-arylcarboxylates without the addition of cofactors. Previously, we designed an AMDase variant G74C/C188S that displays totally inverted enantioselectivity. However, the variant showed a 20,000-fold reduction in activity compared with the wild-type AMDase. Further studies have demonstrated that iterative saturation mutagenesis targeting the active site residues in a hydrophobic pocket of G74C/C188S leads to considerable improvement in activity where all positive variants harbor only hydrophobic substitutions. In this study, simultaneous saturation mutagenesis with a restricted set of amino acids at each position was applied to further heighten the activity of the (S)-selective AMDase variant toward -methyl--phenylmalonate. The best variant (V43I/G74C/A125P/V156L/M159L/C188G) showed 9,500-fold greater catalytic efficiency k(cat)/K-m than that of G74C/C188S. Notably, a high level of decarboxylation of -(4-isobutylphenyl)--methylmalonate by the sextuple variant produced optically pure (S)-ibuprofen, an analgesic compound which showed 2.5-fold greater activity than the (R)-selective wild-type AMDase.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available